Published financial brief
5005B
IRONWOOD PHARMACEUTICALS INC
- As of
- 2024-12-31
- Source
- Supabase fundamentals
- Calculator
- financial-roic-1.0.0
- Published
- 7/26/2026
2 data notes
- Input provenance requires review.
- One or more values are unavailable.
Exact-period record
Fundamentals
5 reported periods
| Metric | FY 20202020-12-31 | FY 20212021-12-31 | FY 20222022-12-31 | FY 20232023-12-31 | FY 20242024-12-31 |
|---|---|---|---|---|---|
| Financial statements | |||||
| RevenueUSD millions | 389.5 | 413.8 | 410.6 | 442.7 | 351.4 |
| Cost of goods soldUSD millions | 227.6 | 180 | 158.8 | 232.1 | 252.5 |
| Selling, general and administrative expenseUSD millions | —missing | —missing | —missing | —missing | —missing |
| Depreciation and amortizationUSD millions | 3.6 | 1.5 | 1.4 | 1.6 | 2 |
| Net incomeUSD millions | 106.2 | 528.5 | 175.1 | -1,002.2 | 0.9 |
| Operating profit (EBIT)USD millions | 158.3 | 232.2 | 250.3 | 209.1 | 96.9 |
| Income taxesUSD millions | 2.7 | -327.8 | 77.4 | 83.5 | 64.3 |
| Short-term debtUSD millions | 3.1 | 120 | 3.1 | 202.7 | 3.2 |
| Long-term debtUSD millions | 450.6 | 355.8 | 412.9 | 512.9 | 596.3 |
| Cash and equivalentsUSD millions | 364.3 | 621.4 | 657.5 | 92.2 | 88.6 |
| ReceivablesUSD millions | 122.4 | 114 | 115.5 | 129.1 | 81.9 |
| InventoryUSD millions | 0 | 0 | 0 | 0 | 0 |
| PayablesUSD millions | 0.7 | 0.9 | 0.5 | 7.8 | 2.1 |
| Net property, plant and equipmentUSD millions | 25.5 | 22.9 | 20.3 | 18.2 | 15.5 |
| Capital expenditureUSD millions | 1.8 | 0.3 | 0.1 | 0.3 | 0.1 |
| Operating cash flowUSD millions | 168.8 | 261.9 | 273.8 | 183.4 | 103.6 |
| Prepaid expensesUSD millions | —missing | —missing | —missing | —missing | —missing |
| AccrualsUSD millions | 28.4 | 33 | 17.5 | 55.5 | 26.6 |
| EBITDAUSD millions | 161.9 | 233.7 | 251.8 | 210.6 | 98.9 |
| Working capitalUSD millions | 463.7 | 583.5 | 755.1 | -42.8 | 143.5 |
| Working capital requirementUSD millions | 121.7 | 113.1 | 115 | 121.3 | 79.8 |
| Total debtUSD millions | 453.7 | 475.8 | 415.9 | 715.5 | 599.5 |
| Free cash flowUSD millions | 167 | 261.6 | 273.6 | 183.2 | 103.4 |
| Unlevered free cash flowUSD millions | 146.9 | 242.1 | 173 | 204 | 44.7 |
| Returns and ratios | |||||
| ROICratio | 103.8% | 170.7% | 128.3% | 146% | 1.3% |
| Pre-tax ROICratio | 106.4% | 170.7% | 185% | 146% | 98.7% |
| Effective tax rateratio | 2.5% | 0% | 30.6% | 0% | 98.7% |
| Revenue growthratio | -9.1% | 6.2% | -0.8% | 7.8% | -20.6% |
| EBIT / Revenueratio | 40.6% | 56.1% | 61% | 47.2% | 27.6% |
| Revenue / Invested capitalmultiple | 2.62× | 3.04× | 3.04× | 3.09× | 3.58× |
| Cogs Over Revenuesratio | 58.4% | 43.5% | 38.7% | 52.4% | 71.9% |
| Sga Over Revenuesratio | —missing | —missing | —missing | —missing | —missing |
| Da Over Revenuesratio | 0.9% | 0.4% | 0.3% | 0.4% | 0.6% |
| Nfa Over Revenuesratio | 6.5% | 5.5% | 4.9% | 4.1% | 4.4% |
| Wcr Over Revenuesratio | 31.2% | 27.3% | 28% | 27.4% | 22.7% |
| Debt Over Ebitdamultiple | 2.8× | 2.04× | 1.65× | 3.4× | 6.06× |
| St Debt Over Cashmultiple | 0.01× | 0.19× | 0× | 2.2× | 0.04× |
| Interest Over Ebitdamultiple | 0.18× | 0.13× | 0.03× | 0.1× | 0.33× |
| Interest Over Nocf Nicfmultiple | 0.18× | 0.12× | 0.03× | 0.12× | 0.32× |
| Nsf Over Wcrmultiple | -2.97× | -4.43× | -5.69× | 0.91× | -1.07× |
Ask this snapshot
Research assistant
5005B · annualSnapshot 2ca9abc0
Answers use only this published snapshot. The assistant will say when the data is insufficient and does not create forecasts, scenarios, or investment advice.
0 / 2,000